GSK's Vi­iV to lean on long-act­ing HIV port­fo­lio ahead of do­lute­gravir patent ex­pi­ra­tion

GSK’s Vi­iV Health­care is eye­ing 2026 and 2027 for po­ten­tial longer-act­ing ver­sions of its re­spec­tive HIV in­jecta­bles for pre­ven­tion and treat­ment, ex­ec­u­tives said on a me­dia call Wednes­day.

The ef­fort is part of GSK’s plan to bounce back from a key patent ex­pi­ra­tion in April 2028 for do­lute­gravir, its block­buster oral in­te­grase in­hibitor. It launched in 2013 as Tivicay and is now a key com­po­nent of GSK’s two-drug HIV treat­ments: Dova­to and Ju­lu­ca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER